Raw data of gut microbiota, blood metabolome and feces metabolome

In this study, we evaluated the potential of semaglutide to alleviate Diabetes-associated cognitive decline（DACD） in mice with DM. Eight-week-old mice fed a high-fat diet with streptozotocin-induced DM were subcutaneously injected with semaglutide (30 nmol/kg qd) for 12 weeks. Semaglutide treatment increased the relative abundances of g_Alistipes, g_norank_f_Eubacterium_coprostanoligenes, g-_Bacteroides, and g_Parabacteroides, while decreasing the relative abundances of g_ faecalibaculum, g_Colodertribacter, g_GCA-900066575, g_Erysipelatoclostridium, and g_norank_f_Lachnospiraceae. Semaglutide also induced alterations in fecal and serum metabolites, as well as transcriptomic changes in brain tissue, with significant common enrichment in neuroactive ligand-receptor interactions. Furthermore, strong correlations were observed among semaglutide-affected genes, metabolites, and microbiota, as assessed by correlation analysis and integrative modeling. In conclusion, these findings suggest that the protective effects of semaglutide against DACD are likely mediated through the microbiota-gut-brain axis. The data showed the raw data of blood metabolome,feces metabolome and gut microbiota.